AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05110326 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ERGON Technique
Description: * Hot pack for 15 minutes.~* Patient position: Prone with knee flexion approximately 45◦.~* Position of therapist: Standing at the affected side of patient.~* Technique:Massage cream will be applied on the hamstring and overactive or short muscle fibres that are restricted.The instrument will be applied parallel to the muscle fibers, both in a distal to proximal and them proximal to distal direction as needed.Then gentle massage stroking from the origin to the insertion will be performed using the instrument. Instrument Assisted Soft Tissue Mobilization(IASTM) will be applied for 5 minutes.~* Strengthening exercises for quadriceps and hamstring will then be performed.~* Isometrics exercises of Quadriceps: By placing a towel roll below the knee and press and hold for 20 seconds, 5 sets.~* Isometrics exercises Hamstrings: By placing a towel roll below the knee and press and hold for 20 seconds, 5 sets.~* Wall sits: For 10 seconds, 5 sets.
Study NCT05110326 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive Neuromuscular Facilitation (PNF) stretching
Description: * The patient will be laid down prone and moist heat will be given for 15 minutes prior to stretching the hamstrings.~* Then patient will be lying supine with hip in 90⁰ of flexion. Patient's knee will be extended until a very mild stretching sensation is felt in hamstring muscles.~* Then patient will be asked to flex the knee against the resistance applied by hand of therapist.~* The patient will be asked to use a force of around 50% of maximal strength and an isometric form of contraction will be gained in the hamstring muscles. The patient will hold the contraction for 8 seconds and then the therapist command to relax the hamstring muscle.~* Immediately after the muscle relaxation the therapist further stretches the hamstring muscles up to a point where the subject reported a mild to moderate stretching sensation without any pain and will be held for 30 seconds.~* The procedure will be repeated 3 times in every session.~Strengthening Exercises:~* Same as ERGON Group
Study NCT04348071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Participants will receive 10 mg ruxolitinib twice daily.
Study NCT04289558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Nitrite
Description: Single 60 minute infusion at 1 of 4 sequential dose levels (0.16, 0.32, 0.64 and 1.28 mcg/kg/minute). The dose amount will depend on when the participant enters the study
Study NCT04543916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax 50 MG
Description: Escalating doses to determine recommended phase 2 dose (RP2D)
Study NCT04543916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax 100 MG
Description: Escalating doses to determine recommended phase 2 dose (RP2D)
Study NCT04543916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax 200 MG
Description: Escalating doses to determine recommended phase 2 dose (RP2D)
Study NCT04543916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax 400
Description: Escalating doses to determine recommended phase 2 dose (RP2D)
Study NCT04543916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax 600
Description: Escalating doses to determine recommended phase 2 dose (RP2D)
Study NCT04543916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan 60 mg/m2
Description: Intravenously (IV), days 1, 8, and 15
Study NCT04978051 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SoC
Description: The SoC could include respiratory support measures, fluid therapy, antipyretic treatment, postural measures, low-molecular-weight-heparins, corticosteroids, such as dexamethasone, remdesivir and other therapeutic options
Study NCT04543916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax (RP2D)
Description: orally, once per day
Study NCT05088044 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: training porogram
Description: training on modified early warning signs will be given to staff nurses and they will be asked to mark physiological parameters on MEWS chart and identify detrioration
Study NCT05468645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]Hemay005
Description: Name: \[14C\]Hemay005 Dose: 60 mg/100 µCi Storage: store at -10℃ to -30 °C, tightly closed and protected from light.
Study NCT06231706 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prebiotic-like nut and seed mix
Description: A mixture of nuts, seeds and other plant based ingredients.
Study NCT06231706 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Bread Crouton
Description: A commercially available bread crouton product.
Study NCT06231706 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Probiotic capsule
Description: Contains the single strain Lactobacillus rhamnosus GG at 15 billion CFUs per capsule.
Study NCT06231706 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: White bread and low fat spread
Description: Consists of 3 slices of bread (providing approx. 55-60g CHO; 3g fibre) + low fat spread (10-15g)
Study NCT06231706 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White bread and low fat spread
Description: Consists of 3 slices of bread (providing approx. 55-60g CHO; 3g fibre) + low fat spread (10-15g)
Study NCT05488704 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Stress Parameters Measurement
Description: Pre-Test (0-2 minutes before NST starts) - Measurement of vital parameters (Pre-Test)~* Glucose measurement~* Taking Salivary Cortisol and Saliva ACTH samples~* Filling the Spielberger State Anxiety Inventory~  • Starting NST by controlling the noise level Interim Test-(NST 10th minute) - Measurement of vital parameters (Intermediate Test)~* Taking Salivary Cortisol and Saliva ACTH samples~* Filling the Spielberger State Anxiety Inventory~  • Termination of NST after 20 minutes Final Test(within 0-2 minutes after NST is over)~* Measurement of vital parameters~* Glucose measurement~* Taking Salivary Cortisol and Saliva ACTH samples~* Filling the Spielberger State Anxiety Inventory After Data Collection - Recording of data~* Centrifugation and analysis of saliva samples taken
Study NCT05172531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisatracurium Besylate
Description: Participants in the test group received Cisatracurium Besylate 0.12mg/kg/hr continuous infusion during intubation。
Study NCT05172531 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: saline 0.12ml/kg/hr
Description: saline 0.12ml/kg/hr
Study NCT05239312 — intervention group
Intervention type: DRUG
Intervention: Antimicrobial
Description: Implementation of antimicrobial protocol for empirical treatment which will be done according to the results of antibiotic susceptibility
Study NCT05705895 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CENTRAL VENOUS CATHETER CARE PROTOCOL
Description: Catheter care is provided in line with the CVC care protocol developed by the researcher:~* For subsequent catheter care, a transparent sterile catheter cover impregnated with 2% chlorhexidine gluconate will be used.~* The entry point of the catheter will be wiped with a disposable sterile skin cleaning applicator containing 2% Chlorhexidine Gluconate and 70% Isopropyl Alcohol, which will be provided by the researchers, and wait for it to dry.~* Vein valve/needleless connector will be used.~* Effective manual disinfection of needle-free connectors (hubs) will be ensured before each intervention.~* Needle-free connectors will be replaced every 96 hours at the latest.~* If necessary, the catheter lumen will be washed with a disposable, positive-pressure sterile washing system containing 10 ccs 0.9% sodium chloride to be provided by the investigators.~* Pulsatile give stop give stop technique will be used in the washing process.
Study NCT05878977 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Immune checkpoint inhibitor
Description: Identification of novel predictive and prognostic biomarkers for immunotherapy treatment response in metastatic melanoma
Study NCT05596734 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bivalent BNT162b2 (original/Omi BA.4/BA.5)
Description: Intramuscular injection
Study NCT05596734 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: qIRV (22/23)
Description: Intramuscular injection
Study NCT06027879 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Specific T- Lymphocytes
Description: Peripheral blood mononuclear cells will be collected from the donor and loaded onto Miltenyi Biotec CliniMACS Prodigy® or CliniMACS® Plus where they will be stimulated in vitro with Adenovirus viral-specific antigen(s). The cells are then immunomagnetically labeled with interferon gamma via the cytokine capture system, captured and infused.
Study NCT06336343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Bimekizumab 320 mg via subcutaneous injections. Bimekizumab is a humanized immunoglobulin G1 monoclonal antibody that selectively binds to and neutralizes the biologic functions of both interleukin-17A (IL-17A) and IL-17F, which are known to increase inflammation.
Study NCT05596734 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QIV
Description: Intramuscular injection
Study NCT05596734 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bIRV
Description: Intramuscular injection
Study NCT05596734 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tIRV
Description: Intramuscular injection
Study NCT05271942 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tilt and Tumble
Description: The Tilt and Tumble technique is used to remove the human lens.
Study NCT05271942 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Divide and Conquer
Description: The Divide and Conquer technique is used to remove the human lens.
Study NCT05254756 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bouquet speculum
Description: Quantitative assessments of visualization of cervix, ease-of-use by the provider, and comfort of the patient
Study NCT05254756 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional plastic 2-blade disposable speculum
Description: Quantitative assessments of visualization of cervix, ease-of-use by the provider, and comfort of the patient
Study NCT05340530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The injectable TQD3606
Description: TQD3606 is a fixed-dose combination of meropenem and avibatam.
Study NCT05340530 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: The injectable TQD3606
Description: TQD3606 is a fixed-dose combination of meropenem and avibatam.
Study NCT05340530 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: The injectable TQD3606
Description: TQD3606 is a fixed-dose combination of meropenem and avibatam.
Study NCT05340530 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: meropenem
Description: Meropenem is a carbapenem antibiotic
Study NCT05340530 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avibactam Sodium
Description: Avibactam is beta-lactamase inhibitor.
Study NCT05340530 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: It is a placebo.
Study NCT06130410 — intervention group
Intervention type: BIOLOGICAL
Intervention: COMIRNATY intramuscular injection
Description: Booster injection in the muscle, 1 dose
Study NCT05317026 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vertebroplasty
Description: SBRT consists of radiotherapy treatments hypofractionated in 1 to 5 fractions, at doses considered curative at a precise target volume.~The vertebroplasty will be performed according to the usual procedure at the center in the angiography suite under local anesthesia and conscious sedation~* Introduction of a vertebral needle, under biplanar fluoroscopic guidance, polymethylmethacrylate (PMMA) cement injection.~* Cone-beam volume-CT at the end of the procedure, with the angiography table and c-arm, to evaluate the cement distribution and detect any leak.~* Decubitus position for 2 hours following procedure, then hospital discharge on the same day.
Study NCT05317026 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Stereotactic Body Radiation Therapy only
Description: SBRT consists of radiotherapy treatments hypofractionated in 1 to 5 fractions, at doses considered curative at a precise target volume
Study NCT06512779 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control Group
Description: sleep hygiene education
Study NCT06512779 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Intervention
Description: Surgical Intervention includes uvulopalatopharyngoplasty (UPPP) and transoral robotic surgery (TORS). UPPP involves the removal of the uvula and tonsils, while TORS consists of the removal of the uvula, tonsils, and adipose tissue at the base of the tongue.
Study NCT06512779 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oropharyngeal Training (face-to-face)
Description: Participants will attend face-to-face oropharyngeal training sessions with a therapist in the lab, each lasting 45-60 minutes, 1-2 times per week, over a 12-week intervention period.
Study NCT06512779 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oropharyngeal Training (telerehabilitation)
Description: Participants will attend online oropharyngeal training (telerehabilitation) sessions with a therapist, each lasting 45-60 minutes, 1-2 times per week, over a 12-week intervention period.
Study NCT06512779 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure
Description: Participants will use Continuous Positive Airway Pressure (CPAP) throughout the intervention period.
Study NCT05135572 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Fibromiyalgia and foot pain
Description: Sensory and motor conduction studies will be performed in the lower extremities. Nerve conduction studies will be performed by another physician unaware of the patient's diagnosisFunctional status will be evaluated by using the Turkish version of the Fibromyalgia Impact Questionnaire (FIQ).Neuropathic Pain will be evalutaed by using the Turkish version of the Neuropathic Pain Questionnaire.
Study NCT05135572 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fibromiyalgia and foot pain
Description: Sensory and motor conduction studies will be performed in the lower extremities. Nerve conduction studies will be performed by another physician unaware of the patient's diagnosisFunctional status will be evaluated by using the Turkish version of the Fibromyalgia Impact Questionnaire (FIQ).Neuropathic Pain will be evalutaed by using the Turkish version of the Neuropathic Pain Questionnaire.
Study NCT06400628 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-management education
Description: The base line data will be taken and used as control, while the final result will be utilized as the case
Study NCT06400628 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-management education
Description: The base line data will be taken and used as control, while the final result will be utilized as the case
Study NCT06078527 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cheung-Bearelly Aesthesiometer
Description: The Cheung-Bearelly Aesthesiometer will be used to deliver a range of calibrated stimuli through the channeled flexible laryngoscope to assess sensation of the laryngopharynx.
Study NCT06078527 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transnasal Laryngoscopy
Description: A procedure to examine your larynx (voice box)
Study NCT06078527 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Patient-reported health and behavioral outcomes measures will be administered
Study NCT06715020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FDG
Description: All study participants will undergo one 18F-FDG PET scan.
Study NCT06718309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Patients with squamous cell carcinoma can choose paclitaxel + cisplatin/carboplatin and patients with nonsquamous cell carcinoma can choose pemetrexed + cisplatin/carboplatin. The chemotherapy treatment lasts 3 cycles.
Study NCT06718309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Description: Investigators choose PD-1 or PD-L1 according to drug indication and the immunotherapy lasts 3 cycles preoperatively and 1 year after surgery.
Study NCT06718309 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical resection of lung cancer
Description: Radical resection of lung cancer with lymph node dissection
Study NCT06718309 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: SBRT for primary lung lesion 8Gy\*3F after first cycle of chemoimmunotherapy
Study NCT06717828 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi Exercise
Description: Tai Chi is a moderate-intensity exercise suitable for middle-aged and elderly individuals. Participants will engage in the practice five times a week (three sessions will be in-person teaching, and two will be online), with each session lasting 60 minutes, continuing until the end of a six-month follow-up. Before the intervention begins, participants will receive a manual or instructional video on Tai Chi to understand its principles, practice techniques, and safety precautions. Each class will start with a warm-up and include a review of Tai Chi principles and movements, breathing techniques, and relaxation methods. Participants will document their Tai Chi practice over 24 weeks by submitting exercise weekly logs, while researchers will monitor their exercise progress weekly via phone using standardized forms to assess frequency, completion status, adverse events, and adherence.
Study NCT06717828 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Regular Exercise
Description: The intervention for middle-aged and elderly individuals includes a combination of common activities: 15 minutes of walking, 15 minutes of body coordination activities (including limb movements and balance training), 15 minutes of muscle stretching, and 15 minutes of relaxation. Each exercise session lasts for 60 minutes, conducted five days a week. The heart rate during exercise will be adjusted based on monthly fitness assessments, and the daily activity level will be evaluated through logs and fitness trackers.
Study NCT06717828 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control
Description: All participants will be advised not to change their existing lifestyle habits and will only receive health education related to fatty liver throughout the intervention. The educational methods will include large group sessions, individual education, and telephone follow-ups, conducted every two months. Additionally, dietary and exercise assessments will be carried out during the intervention, with dietary intake recorded using a three-day food diary to track daily calorie consumption.
Study NCT04750070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dopamine
Description: Children will receive dopamine, 8 microgram/kg.min (increasing the dose after 15 minutes to 12 microgram/kg/min to a maximum of 15 microgram/kg/min)
Study NCT04750070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adrenaline
Description: Children will receive adrenaline, 0.1 microgram/kg/min (increasing the dose after 15 minutes to 0.2 microgram/kg.min to a maximum of 0.3 microgram/kg.min)
Study NCT04750070 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Blood Transfusion
Description: Children will receive a transfusion of whole human blood in a dose of 10 mL/kg over 2-3 hours. While the blood transfusion is being arranged, IV fluid would be given @ of 3 ml per kg per hour
Study NCT04929067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: immunotherapy combined with neoadjuvant chemotherapy in patients with locally advanced HPV (-) head and neck squamous cell carcinoma
Description: immunotherapy combined with neoadjuvant chemotherapy in patients with locally advanced HPV (-) head and neck squamous cell carcinoma
Study NCT05048251 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cTBS
Description: continuous theta burst stimulation
Study NCT05048251 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iTBS
Description: intermittent theta burst stimulation
Study NCT05048251 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham
Description: sham stimulation
Study NCT05704920 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IA
Description: The multidisciplinary team meeting discussion is informed of the AI-based analysis of their chest computed tomography
Study NCT05704920 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Not IA
Description: The multidisciplinary team meeting discussion is not informed of the AI-based analysis of their chest computed tomography
Study NCT05882617 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: implants supported overdentures
Description: implant supported and retained with different number of implants retained by ball attachments
Study NCT05882617 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: implants supported overdentures
Description: implant supported and retained with different number of implants retained by ball attachments
Study NCT05882617 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: implants supported overdentures
Description: implant supported and retained with different number of implants retained by ball attachments